Powered by

Gala Enrolls First Subject at Temple Lung Center as Part of the US Early Feasibility Trial of RheOx(TM) for Chronic Bronchitis in the United States

Jan 17, 2019 - PR Newswire
Partnership Announcement

PR Newswire

 Gala Therapeutics (Gala), a clinical-stage developer of medical devices to treat pulmonary disease, today announced that the first patient at Temple Lung Center in Philadelphia, Pennsylvania was treated on January 15th, 2019 as part of the Early Feasibility Study of RheOx(TM) for chronic bronchitis.  Dr. Victor Kim, a leading expert in chronic bronchitis, performed the procedure.

"We are excited to offer this new bronchoscopic method of treating chronic bronchitis by ...